227 related articles for article (PubMed ID: 32634120)
21. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.
Grau L; Gitomer B; McNair B; Wolf M; Harris P; Brosnahan G; Torres V; Steinman T; Yu A; Chapman A; Chonchol M; Nowak KL
Kidney360; 2020 Jul; 1(7):648-656. PubMed ID: 33305291
[TBL] [Abstract][Full Text] [Related]
22. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
[TBL] [Abstract][Full Text] [Related]
23. PKD1 Truncating Mutations Accelerate eGFR Decline in Autosomal Dominant Polycystic Kidney Disease Patients.
Ali H; Alahmad B; Senum SR; Warsame S; Bahbahani Y; Abu-Farha M; Abubaker J; Alqaddoumi M; Al-Mulla F; Harris PC
Am J Nephrol; 2024; 55(3):380-388. PubMed ID: 38194940
[TBL] [Abstract][Full Text] [Related]
24. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM; Senum SR; Le Meur Y; Torres VE; Harris PC
Nephrol Dial Transplant; 2018 Apr; 33(4):645-652. PubMed ID: 28992127
[TBL] [Abstract][Full Text] [Related]
25. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
26. Genotype-Clinical Correlations in Polycystic Kidney Disease with No Apparent Family History.
Sekine A; Fujimaru T; Hoshino J; Suwabe T; Oguro M; Mizuno H; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Mandai S; Chiga M; Kikuchi H; Ando F; Mori T; Sohara E; Uchida S; Sawa N; Takaichi K; Ubara Y
Am J Nephrol; 2019; 49(3):233-240. PubMed ID: 30820006
[TBL] [Abstract][Full Text] [Related]
27. Analysis of baseline parameters in the HALT polycystic kidney disease trials.
Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT; Hogan MC; Oskoui FR; Kelleher C; Masoumi A; Glockner J; Halin NJ; Martin DR; Remer E; Patel N; Pedrosa I; Wetzel LH; Thompson PA; Miller JP; Meyers CM; Schrier RW;
Kidney Int; 2012 Mar; 81(6):577-85. PubMed ID: 22205355
[TBL] [Abstract][Full Text] [Related]
28. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
29. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
Borrego Utiel FJ; Esteban de la Rosa RJ; Merino García E; Medina Benítez A; Polo Moyano A; Moriana Domínguez C; Morales García AI; Bravo Soto JA
Am J Nephrol; 2021; 52(8):630-641. PubMed ID: 34518464
[TBL] [Abstract][Full Text] [Related]
30. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
31. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
32. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
[TBL] [Abstract][Full Text] [Related]
33. Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome Sequencing.
Kim H; Park HC; Ryu H; Kim H; Lee HS; Heo J; Lee C; Kim NKD; Park WY; Hwang YH; Lee KB; Oh KH; Oh YK; Ahn C
Sci Rep; 2019 Nov; 9(1):16952. PubMed ID: 31740684
[TBL] [Abstract][Full Text] [Related]
34. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
[TBL] [Abstract][Full Text] [Related]
35. A novel PKD1 variant demonstrates a disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant polycystic kidney disease.
Ali H; Hussain N; Naim M; Zayed M; Al-Mulla F; Kehinde EO; Seaburg LM; Sundsbak JL; Harris PC
BMC Nephrol; 2015 Mar; 16():26. PubMed ID: 25880449
[TBL] [Abstract][Full Text] [Related]
36. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
37. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
McKenzie KA; El Ters M; Torres VE; Harris PC; Chapman AB; Mrug M; Rahbari-Oskoui FF; Bae KT; Landsittel DP; Bennett WM; Yu ASL; Mahnken JD
BMC Nephrol; 2018 Dec; 19(1):378. PubMed ID: 30591038
[TBL] [Abstract][Full Text] [Related]
38. Mutational analysis in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): Identification of five mutations in the PKD1 gene.
Abdelwahed M; Hilbert P; Ahmed A; Mahfoudh H; Bouomrani S; Dey M; Hachicha J; Kamoun H; Keskes-Ammar L; Belguith N
Gene; 2018 Sep; 671():28-35. PubMed ID: 29860066
[TBL] [Abstract][Full Text] [Related]
39. Urinary biomarkers at early ADPKD disease stage.
Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
[TBL] [Abstract][Full Text] [Related]
40. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.
Girardat-Rotar L; Braun J; Puhan MA; Abraham AG; Serra AL
BMC Nephrol; 2017 Jul; 18(1):241. PubMed ID: 28716055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
